Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 26;13:1012723. doi: 10.3389/fphar.2022.1012723

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Kim, Chung, Dennis, Yoshida, Aguiar, Aller, Mendes, Schmid, Sabater, Baumlin and Salathe.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

VG and PG/VG e-cig aerosols impair nasal CFTR function in vivo. (A) Consolidated Standards of Reporting Trials diagram demonstrating the flow of participants and their samples used in this study. Compliance was defined as initiating at least 40 puffs per day with ≥ 200 s daily puff time. Nasal potential difference (NPD) recordings and nasal brushings were collected at baseline and Day 8. (B) Example NPD recordings from a volunteer who vaped VG e-liquid performed at initial (baseline) and final (Day 8) visits. (C) Before-after plots of nasal CFTR function (measured as change following “Zero Cl⁻” and “Isoproterenol” treatments) from all volunteers at baseline (BL) and at Day 8 after one week of vaping. n = 7. The reduction in nasal CFTR activity is seen in all volunteers who inhaled aerosol generated from e-liquids containing VG (PG/VG and VG only; n = 3).